From Science to Scandal: How Politicization is Redrawing the Healthcare Playbook.

November 2025

Healthcare is uniquely vulnerable to politicization because lives, livelihoods, and public budgets are at stake. Politicization has always existed in healthcare, but the speed and reach of today’s information environment mean scientific claims are now weaponized in hours, not months.¹ The consequences are immediate: delayed access, eroded trust, fragmented standards of care, and uneven adoption of prevention and treatment.²

For healthcare leaders, this is no longer a “policy background” issue. Politicization now shapes capital allocation, launch sequencing, pricing architecture, workforce stability, and license-to-operate in every major market.^1,3

What “Politicization of Science” Means for Healthcare

The academic literature is clear that politicization is not simply “politics touching science”; it is a specific pattern where scientific claims become cues for group identity and partisan conflict:

• Schmid-Petri and colleagues describe politicization as the process through which scientific issues move into electoral competition and media conflict, with politicians, media, and scientists together shaping whether science is seen as neutral guidance or “just another opinion.”²
• Pielke distinguishes between scientists who act as honest brokers—laying out decision options—and those who become issue advocates, backing a single policy outcome. When scientists or institutions are perceived as advocates, trust in their evidence erodes among opponents, even if the underlying data are strong.³
• Strassheim and Kettunen warn that evidence-based policy can flip into policy-based evidence, with governments selectively commissioning or cherry-picking studies that support an already chosen course of action.⁴

Druckman’s work on recent crises shows how politicization interacts with misinformation and inequality: partisan cues shape risk perceptions; misinformation and disinformation exploit those divisions; and existing social inequalities determine who bears the brunt when science-based guidance is ignored.^1,5,6 Over time, public trust in science itself becomes polarized.⁷

For healthcare, this dynamic is particularly dangerous: once clinical guidance is coded as “for” or “against” a political tribe, even high-quality evidence can lose its authority at the bedside and in the budget process.^1–3 For C-suite leaders, the message is stark: politicization is no longer a headline risk—it is a structural feature of the operating environment.

Some of the Regional Fault Lines Corporate Leaders Must Track

United States – insurance subsidies and women’s health

Enhanced marketplace premium tax credits are scheduled to expire on December 31, 2025, and Congress is actively debating whether to extend, modify, or let them lapse. Competing bipartisan and Republican proposals range from short extensions with integrity guardrails to shifting support into HSAs. If the enhancements lapse, 2026 net premiums would rise sharply for many enrollees.^6,9,10 At the same time, reproductive health is being reframed not just as a clinical matter but as a battleground for state and federal authority, with state-level policies expanding or restricting access and, in some cases, criminalizing aspects of care.¹¹

Implication: National brands face a patchwork in which the same clinical service may be subsidized, restricted, or criminalized across jurisdictions. Corporate Affairs must anticipate litigation, employee-relocation implications, and market restrictions from both sides of the debate.

Europe – EU HTA and chemicals policy

From January 2025, the EU Health Technology Assessment Regulation (HTAR) phases in joint clinical assessments (JCA) for high-impact therapies, changing how evidence is generated, scrutinized, and shared across Member States.^8,12,13 Under the HTAR, starting in January 2025, relative clinical effectiveness for certain cancer medicines and advanced therapy medicinal products will be assessed via joint clinical assessments conducted by Member States’ HTA bodies.^8,13,14 JCAs for orphan medicines will commence in 2028, with the remaining new medicines in 2030. National pricing/reimbursement is still outside the JCA scope.

In parallel, the EU Chemicals Strategy for Sustainability introduced stricter controls on hazardous substances, including PFAS, and a new “essential use” to limit the use of the most harmful chemicals to cases where they are necessary for health, safety, or critical societal functions and where no acceptable alternatives exist.^9,15,16  This proposal is still under review.

Implication: Evidence standards themselves are politicized. Life-science and chemical companies must engage upstream in HTA and chemicals-policy debates or risk having rules written around politically salient cases rather than robust comparative effectiveness.

Asia / India – expanding public insurance

India has implemented Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB PM-JAY), an expansion of the scheme for all seniors aged 70+, issuing distinct cards and senior top-ups; eligibility extends even to seniors with private or ESIC coverage.^10,17,18 This expansion is framed as a universalist move towards greater equity and financial protection for older adults.

Implication: The policy is politically attractive; however, it raises questions about long-term fiscal sustainability, provider reimbursement, and potential crowd-out of private coverage. Companies will need scenario plans for premium, formulary, and co-pay changes as fiscal pressures intensify.

Australia – affordability as a political fault line

Polling in Australia shows that around half of adults have postponed treatment due to cost, and about three-quarters report difficulty finding bulk-billing doctors.^12,19–21 In response, the federal government has tripled—and is now further expanding—bulk-billing incentives, describing this as the most significant investment in Medicare’s history, with a goal of making nine out of ten GP visits bulk billed by 2030.^13,21–23 From 1 Nov 2025, bulk‑billing incentives apply to all patients, and fully bulk‑billing practices receive an extra 12.5% loading via the new BBPIP.

Implication: Affordability narratives now drive both regulatory pressure on prices and public expectations of “fair” margins. Companies should explicitly link their pricing strategies to access, outcomes, equity, and system sustainability.

Middle East – conflict-driven system collapse

In Gaza, repeated attacks on health facilities and sustained hostilities have pushed the health system to the brink of total collapse. UN human rights reporting and WHO situation updates document extensive damage to hospitals, severe shortages of medical supplies, and large-scale displacement undermining access to care.^14,24–26

Implication: In fragile states, the distinction between humanitarian healthcare, commercial activity, and geopolitical signaling is blurring. Boards need clear policies on operating thresholds, partnerships, and exit triggers.

Africa – workforce and financing stress

Across Africa, recognition of chronic health-worker shortages has led to the co-creation and launch of the Africa Health Workforce Investment Charter, endorsed at the Africa Health Workforce Investment Forum in 2024. ^15,27–29 The charter commits governments and partners to coordinated, long-term investment in training, job creation, and protection of health workers as a foundation for resilient systems.

Implication: Corporate strategies that ignore workforce capacity risk being perceived as extractive. Investor and donor coalitions are increasingly asking whether new technologies come with training, task-shifting, and digital tools that could genuinely expand system capacity.

A Disciplined Playbook for De-Politicizing Healthcare Decisions 

Against this backdrop, C-suite leaders cannot “wait out” politicization. They need a structured, healthcare-specific response that protects evidence integrity while recognizing that values and access choices are inherently political.

Step 1: Reinforce independence in clinical and public-health research

Politicization is most corrosive when stakeholders suspect that evidence is being generated to reach a pre-agreed conclusion. The literature on policy-based evidence is clear: once that perception takes hold, even high-quality science is downgraded to “just another lobbyist.” ^2,4

Practical moves

• Separate funding and design decisions from business units with direct commercial stakes.
• Use independent steering committees, pre-registered protocols, and external data-monitoring boards—and disclose these safeguards publicly.
• Where feasible, pre-commit to publishing results irrespective of outcome.

Step 2: Walk the talk on transparency and uncertainty

Research on misinformation shows that when uncertainty and evolving evidence are not acknowledged directly, communication vacuums are filled with “alternative facts” that can persist even after correction.^1,5

Practical moves

• Publish plain-language, patient-relevant summaries alongside technical reports.
• Explicitly state what is known, unknown, and likely to change—then revisit these statements on a visible update cadence.
• Train spokespeople to answer “What would change your mind?” and make that part of public messaging.

Step 3: Speak out – strategically and in coalitions 

Studies on counteracting politicization in science communication show that timely, evidence-based corrections—especially when delivered by diverse, cross-party coalitions—can reduce misperceptions without backfiring.^1,2

Practical moves

• Pre-identify red-line misuses of your data or products (e.g., safety claims, off-label narratives) that will trigger rapid response.
• Speak through coalitions that include clinicians, patient groups, and professional societies rather than as a lone company voice.
• Use real-world patient stories to anchor abstractions in lived experience.

Step 4: Build proactive coalitions and shared guardrails

Because politicization emerges from the interaction of politics, information groups, and science, governance must also be multi-actor.^2,3,4

Practical moves

• Convene coalitions to agree on minimum standards for evidence claims in your therapy area (e.g., correctly citing primary sources; correcting errors within defined timelines; avoiding cherry-picked comparator data).
• Develop joint “rules of the game” for how value-laden issues (equity, affordability, prioritization) will be handled once the facts are agreed.

Step 5: Invest in health literacy and community partnerships

Druckman and others highlight how structural inequalities in access to information and participation in science make some groups both more vulnerable to harm and less represented in the evidence base.^1,5,6

Practical moves

• Co-design literacy initiatives with community organizations, schools, and faith-based groups, focusing on risk–benefit, uncertainty, and how to interpret competing claims.
• Support inclusive research designs that reach underrepresented populations, drawing on community-based sampling and partnership approaches.^1,5

Step 6: Plan before the storm

Given the regional trends above, healthcare politicization is predictable enough to plan for.

Practical moves

• Map your exposure to hot-button issues (e.g., reproductive health, vaccines, AI in diagnostics, high-cost gene therapies, chemicals of concern).
• For each, define engagement red lines (what your organization will not do), escalation paths (who decides when to speak publicly), and off-ramps (how to de-escalate once engaged).
• Stress-test supply chains, pricing strategies, and patient-support programs against plausible policy shocks in each priority market.

How Confident Strategy Group Can Help

Confident Strategy Group has over 20 years of experience in mitigating politicization at the forefront of science and health worldwide. Our healthcare work starts from this evidence base: the politicization of healthcare as a structural, not episodic, feature of modern healthcare. We employ a sequential approach focused on independence safeguards, transparency architecture, coalition governance, literacy initiatives, and escalation/off-ramp design. This framework keeps care decisions anchored in evidence even when politics are inflamed.^1–4 We do this by working across all three stakeholder spectrums.

Our ConfidentAccess™ process can be tailored to:

• Build a global and country-specific politicization risk matrix across your portfolio
• Diagnose vulnerabilities in your current evidence-generation, communication, and coalition strategy
• Design a 90-day action plan with clear accountabilities for Corporate Affairs, R&D, Market Access, and Sustainability (ESG) teams

If you are leading Corporate Affairs, Market Access, or Sustainability (ESG) for a healthcare organization and recognize elements of your portfolio in the regional patterns above. In that case, this is the moment to move from ad hoc firefighting to a deliberate modern architecture. We would welcome a conversation on how to make your organization politicization-resilient while staying firmly grounded in science and patient value.

References:

1. Druckman JN. Threats to science: politicization, misinformation, and inequalities. Ann Am Acad Pol Soc Sci. 2022;700(1):8-24. Available at: https://journals.sagepub.com/doi/10.1177/00027162221095431.
2. Schmid-Petri H, Bienzeisler N, Beseler A. Effects of politicization on the practice of science. Prog Mol Biol Transl Sci. 2022;190:71-95. Available at: https://www.sciencedirect.com/science/article/pii/S1877117321002143.
3. Pielke RA Jr. When scientists politicize science. In: The Honest Broker: Making Sense of Science in Policy and Politics. Cambridge, UK: Cambridge University Press; 2007:116-134. Available at: https://www.cambridge.org/core/books/honest-broker/when-scientists-politicize-science/1B59773E26A77305BBC92750B2490303.
4. Strassheim H, Kettunen P. When does evidence-based policy turn into policy-based evidence? Configurations, contexts, and mechanisms. Evid Policy. 2014;10(2):259-277. Available at: https://bristoluniversitypressdigital.com/view/journals/evp/10/2/article-p259.xml.
5. Druckman JN. Threats to science: politicization, misinformation, and inequalities (working paper version). Institute for Policy Research, Northwestern University; 2021. Available at: https://www.ipr.northwestern.edu/documents/working-papers/2021/wp-21-52.pdf.
6. Gauchat G. Politicization of science in the public sphere: a study of public trust in the United States, 1974–2010. Am Sociol Rev. 2012;77(2):167-187. Available at: https://journals.sagepub.com/doi/10.1177/0003122412438225.
7. Curhan T, Fairbanks M, Forouzan K, Jemmott NS, Mariappuram R. State policy trends midyear analysis: abortion ban exceptions, criminalization, maternal mortality, and attacks on youth access. Guttmacher Institute; June 2025. Available at: https://www.guttmacher.org/2025/06/state-policy-trends-midyear-analysis.
8. European Commission. Joint clinical assessments—implementation of the Health Technology Assessment Regulation. Available at: https://health.ec.europa.eu/health-technology-assessment/implementation-regulation-health-technology-assessment/joint-clinical-assessments_en.
9. European Commission. Guiding criteria and principles for the ‘essential use’ concept in EU legislation dealing with chemicals. Communication C(2024) 1995 final. 2024. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:C_2024_289_01.
10. Press Information Bureau, Government of India. Ayushman Bharat becomes bigger: world’s largest health insurance scheme extends free health cover to all senior citizens above 70 years. Press note; September 12, 2024. Available at: https://pib.gov.in/PressNoteDetails.aspx?NoteId=152133.
11. Kaul R. Cabinet approves ₹5 lakh health cover for senior citizens 70 and above. Hindustan Times. September 12, 2024. Available at: https://www.hindustantimes.com/india-news/cabinet-approves-5-lakh-health-cover-for-senior-citizens-101726081277795.html.
12. Whittaker J. Healthcare affordability crisis poll shows millions skipping treatment and struggling to find bulk-billing doctors. ABC News (Australia). October 27, 2024. Available at: https://www.abc.net.au/news/2024-10-28/healthcare-costs-bulk-billing-medicare-polling-yougov-dental/104518336.
13. Australian Government, Department of Health, Disability and Ageing. Bulk billing incentives in general practice. Updated November 20, 2025. Available at: https://www.health.gov.au/our-work/bulk-billing-incentives-in-general-practice.
14. World Health Organization. Health system at breaking point as hostilities further intensify, WHO warns. News release; May 22, 2025. Available at: https://www.who.int/news/item/22-05-2025-health-system-at-breaking-point-as-hostilities-further-intensify–who-warns.
15. World Health Organization Regional Office for Africa. Africa health workforce investment charter: enabling sustainable health workforce. 2024. Available at: https://www.afro.who.int/publications/africa-health-workforce-investment-charter-enabling-sustainable-health-workforce.
16. The Global Fund to Fight AIDS, Tuberculosis, and Malaria. Global Fund hails launch of Africa Health Workforce Investment Charter. News release; May 6, 2024. Available at: https://www.theglobalfund.org/en/news/2024/2024-05-06-global-fund-hails-launch-africa-health-workforce-investment-charter/.
17. Collins S, Corlette S, Wengle E. How the budget reconciliation bill will make marketplace coverage less affordable and undermine abortion access for many. The Commonwealth Fund. June 25, 2025. Available at: https://www.commonwealthfund.org/publications/explainer/2025/jun/how-budget-bill-will-make-marketplace-coverage-less-affordable.